All Semaglutide Brands in India 2026: Complete Comparison Guide

A Guide to Semaglutide in India

The conversation around health and wellness in India is evolving, and with it comes a growing interest in new medical treatments. One name you may have heard is semaglutide, a medication that has gained significant attention globally. Originally developed for managing type 2 diabetes, its effects on weight have made it a topic of discussion for chronic weight management as well.

As more options become available, understanding the landscape can feel overwhelming. This guide aims to provide a clear and practical overview of the semaglutide brands available in India in 2026. Our goal is to equip you with balanced information so you can have a more informed conversation with your doctor. Consult your healthcare provider before starting any medication.

How Does Semaglutide Work?

To understand the different brands, it helps to first understand the medication itself. Semaglutide belongs to a class of drugs called GLP-1 (glucagon-like peptide-1) receptor agonists.

In simple terms, it works by mimicking a natural hormone in your body called GLP-1. This hormone is released in the gut after you eat and plays a key role in managing your blood sugar and appetite.

By acting like GLP-1, semaglutide helps to:

• Regulate appetite: It signals to the brain that you are full, which can lead to eating less.
• Slow down digestion: It keeps food in your stomach for longer, contributing to a feeling of fullness.
• Support blood sugar control: For people with type 2 diabetes, it helps the pancreas release the right amount of insulin when blood sugar is high.

Semaglutide is available in two forms: a once-weekly injection and a once-daily oral tablet.

Semaglutide Brands in India (2026)

The Indian market for semaglutide includes globally recognized brands and is seeing the emergence of local pharmaceutical innovation. Here’s a look at the key players.

Ozempic (Injectable)

Ozempic, from the Danish pharmaceutical company Novo Nordisk, was one of the first semaglutide products to become widely available.

• Formulation: It is a once-weekly injectable pen.
• Primary Approved Use: Novo Nordisk launched Ozempic in India in December 2025 and markets it there only for type 2 diabetes. It is prescribed to help improve blood sugar control in adults, alongside diet and exercise.
• What to Know: It comes in a pre-filled pen, which is designed for self-administration after proper training from a healthcare professional.

Rybelsus (Oral)

Also from Novo Nordisk, Rybelsus represents a significant development as the first oral tablet in the GLP-1 class.

• Formulation: It is a once-daily tablet.
• Primary Approved Use: Like Ozempic, Rybelsus is approved in India for managing type 2 diabetes in adults.
• What to Know: Its main distinction is convenience for those who prefer a tablet over an injection. It has specific administration requirements—it must be taken on an empty stomach with a small amount of water, at least 30 minutes before any other food, drink, or medication.

Wegovy (Injectable)

Wegovy is another injectable semaglutide from Novo Nordisk, but it is specifically positioned for a different purpose.

• Formulation: It is a once-weekly injectable pen.
• Primary Approved Use: Wegovy is approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related health condition.
• What to Know: Wegovy was launched in India in June 2025 in five strengths (0.25 mg to 2.4 mg). While it contains the same active ingredient as Ozempic (semaglutide), Wegovy goes up to a higher weekly dose and is prescribed specifically for weight management goals, as part of a comprehensive plan that includes a reduced-calorie diet and increased physical activity.

Indian Semaglutide Brands Launched in March 2026

The semaglutide patent expired in India in March 2026, and several Indian companies launched their own semaglutide injections from March 21, 2026. Examples include Obeda (Dr. Reddy's), GLIPIQ (Glenmark), Semasize, Obesema and Hepaglide (Alkem), Noveltreat and Sematrinity (Sun Pharma), and Semaglyn, Mashema and Alterme (Zydus, co-marketed by Lupin as Semanext and Livarise).

These products contain the same active ingredient, semaglutide, and were approved by the Central Drugs Standard Control Organisation (CDSCO). Approved uses differ by brand: for example, Obeda and GLIPIQ were launched for type 2 diabetes, Sun Pharma's Noveltreat for chronic weight management, and Zydus's brands for both type 2 diabetes and weight management. Devices also differ (disposable pens, reusable pens with cartridges, and vials). Check the exact brand, indication and device with your doctor and pharmacist. Brand availability can change, so this list reflects launches announced as of October 2026.

Comparing the Brands: A Practical Overview

Choosing between different semaglutide options is a decision made with a doctor. Here are the key factors that differentiate the brands.

Injection vs. Oral Tablet

This is often the most straightforward difference.

• Injectable (Ozempic, Wegovy): A once-a-week injection may be seen as more convenient by some, as it doesn't require a daily routine.
• Oral (Rybelsus): A daily tablet appeals to those who are uncomfortable with needles. However, it requires a strict morning routine to ensure it is absorbed properly.

Approved Medical Use

The approved indication is a critical distinction.

• For Type 2 Diabetes: Ozempic, Rybelsus and several of the newer Indian brands are approved for blood sugar control.
• For Chronic Weight Management: Wegovy is the Novo Nordisk brand approved for this purpose, and some newer Indian brands also carry a weight-management indication.

A doctor will evaluate your overall health profile to determine which medication, if any, is appropriate for your specific condition.

Dosing and Titration

All semaglutide medications are started at a low dose and gradually increased over several weeks or months. This process, called titration, helps the body adjust to the medication and minimizes potential side effects. The exact dosing schedule for Ozempic, Wegovy, and Rybelsus differs, and your doctor will manage this process carefully.

Safety and Important Considerations

Like any prescription medication, semaglutide has potential side effects. The most common ones are gastrointestinal, such as nausea, vomiting, diarrhea, constipation, and abdominal pain. For most people, these are mild to moderate and tend to decrease over time as their body gets used to the medication.

Less common but serious problems can include pancreatitis (severe stomach pain that does not go away and may spread to your back), gallbladder problems, dehydration that can affect the kidneys, low blood sugar when used with insulin or sulfonylureas, worsening diabetic eye disease, and serious allergic reactions. Seek urgent medical help for any of these. Semaglutide should not be used in pregnancy, and it should be stopped at least 2 months before a planned pregnancy. Tell your doctor or anaesthetist that you take it before any surgery or sedation.

It is crucial to take semaglutide under the supervision of a qualified healthcare professional. They can help you manage any side effects, monitor your progress, and ensure the treatment is right for you. At Weight Easy, we believe that clear information helps you have more informed conversations with your doctor.

Making an Informed Decision

The growing number of semaglutide options in India provides more tailored choices for patients. However, the best choice is not about a brand name but about your individual health needs. Your medical history, primary health goal (diabetes control or weight management), lifestyle, and personal preferences are all important factors.

This guide is intended to be a starting point for a conversation, not a substitute for professional medical care. The journey to better health is personal, and the right treatment plan is one you build in partnership with a trusted medical expert. Consult your healthcare provider before starting any medication.

Sources

• Central Drugs Standard Control Organisation (CDSCO): https://cdsco.gov.in
• World Health Organization (WHO) - Obesity and Overweight: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
• Novo Nordisk Global: https://www.novonordisk.com
• Semaglutide, T2DM, and Cardiovascular Outcomes (NEJM Study): https://pubmed.ncbi.nlm.nih.gov/27633186/
• Indian Council of Medical Research (ICMR): https://www.icmr.gov.in
• Ozempic India launch for type 2 diabetes (Storyboard18), December 2025: https://www.storyboard18.com/brand-marketing/novo-nordisk-launches-ozempic-in-india-for-type-2-diabetes-aligns-pricing-with-wegovy-85831.htm
• Wegovy India launch and price update (BioSpectrum India), November 2025: https://www.biospectrumindia.com/public/news/73/26916/novo-nordisk-india-reduces-wegovy-prices-for-patient-benefit.html
• Ozempic prescribing information (FDA): https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• Glenmark GLIPIQ launch release, March 21, 2026: https://glenmarkpharma.com/gpl_pdfs/media/PR_Glenmark%20Pharmaceuticals%20launches%20GLIPIQ%E2%93%87.pdf
• Dr. Reddy's Obeda launch release, March 21, 2026: https://www.drreddys.com/cms/sites/default/files/2026-03/finalpressrelease-Dr.Reddy%27sSemalaunch-21stMarch2026.pdf
• Sun Pharma semaglutide launch release, March 2026: https://sunpharma.com/wp-content/uploads/2026/03/SEintimationPRforSemaglutide.pdf
• Zydus semaglutide launch (BioSpectrum India), March 21, 2026: https://www.biospectrumindia.com/news/73/27523/zydus-launches-semaglutide-injection-in-reusable-multi-dose-pen-device-in-india.html